Repository logo
 
Publication

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

dc.contributor.authorBastard, Paul
dc.contributor.authorVazquez, Sara E.
dc.contributor.authorLiu, Jamin
dc.contributor.authorLaurie, Matthew T.
dc.contributor.authorWang, Chung Yu
dc.contributor.authorGervais, Adrian
dc.contributor.authorLe Voyer, Tom
dc.contributor.authorBizien, Lucy
dc.contributor.authorZamecnik, Colin
dc.contributor.authorPhilippot, Quentin
dc.contributor.authorRosain, Jérémie
dc.contributor.authorCatherinot, Emilie
dc.contributor.authorWillmore, Andrew
dc.contributor.authorMitchell, Anthea M.
dc.contributor.authorBair, Rebecca
dc.contributor.authorGarçon, Pierre
dc.contributor.authorKenney, Heather
dc.contributor.authorFekkar, Arnaud
dc.contributor.authorSalagianni, Maria
dc.contributor.authorPoulakou, Garyphallia
dc.contributor.authorSiouti, Eleni
dc.contributor.authorSahanic, Sabina
dc.contributor.authorTancevski, Ivan
dc.contributor.authorWeiss, Günter
dc.contributor.authorNagl, Laurenz
dc.contributor.authorManry, Jérémy
dc.contributor.authorDuvlis, Sotirija
dc.contributor.authorArroyo-Sánchez, Daniel
dc.contributor.authorPaz Artal, Estela
dc.contributor.authorRubio, Luis
dc.contributor.authorPerani, Cristiano
dc.contributor.authorBezzi, Michela
dc.contributor.authorSottini, Alessandra
dc.contributor.authorQuaresima, Virginia
dc.contributor.authorRoussel, Lucie
dc.contributor.authorVinh, Donald C.
dc.contributor.authorReyes, Luis Felipe
dc.contributor.authorGarzaro, Margaux
dc.contributor.authorHatipoglu, Nevin
dc.contributor.authorBoutboul, David
dc.contributor.authorTandjaoui-Lambiotte, Yacine
dc.contributor.authorBorghesi, Alessandro
dc.contributor.authorAliberti, Anna
dc.contributor.authorCassaniti, Irene
dc.contributor.authorVenet, Fabienne
dc.contributor.authorMonneret, Guillaume
dc.contributor.authorHalwani, Rabih
dc.contributor.authorSharif-Askari, Narjes Saheb
dc.contributor.authorDanielson, Jeffrey
dc.contributor.authorBurrel, Sonia
dc.contributor.authorMorbieu, Caroline
dc.contributor.authorStepanovskyy, Yurii
dc.contributor.authorBondarenko, Anastasia
dc.contributor.authorVolokha, Alla
dc.contributor.authorBoyarchuk, Oksana
dc.contributor.authorGagro, Alenka
dc.contributor.authorNeuville, Mathilde
dc.contributor.authorNeven, Bénédicte
dc.contributor.authorKeles, Sevgi
dc.contributor.authorHernu, Romain
dc.contributor.authorBal, Antonin
dc.contributor.authorNovelli, Antonio
dc.contributor.authorNovelli, Giuseppe
dc.contributor.authorSaker, Kahina
dc.contributor.authorAilioaie, Oana
dc.contributor.authorAntolí, Arnau
dc.contributor.authorJeziorski, Eric
dc.contributor.authorRocamora-Blanch, Gemma
dc.contributor.authorTeixeira, Carla
dc.contributor.authorDelaunay, Clarisse
dc.contributor.authorLhuillier, Marine
dc.contributor.authorLe Turnier, Paul
dc.contributor.authorZhang, Yu
dc.contributor.authorMahevas, Matthieu
dc.contributor.authorPan-Hammarström, Qiang
dc.contributor.authorAbolhassani, Hassan
dc.contributor.authorBompoil, Thierry
dc.contributor.authorDorgham, Karim
dc.contributor.authorGorochov, Guy
dc.contributor.authorLaouenan, Cédric
dc.contributor.authorRodríguez-Gallego, Carlos
dc.contributor.authorNg, Lisa F. P.
dc.contributor.authorRenia, Laurent
dc.contributor.authorPujol, Aurora
dc.contributor.authorBelot, Alexandre
dc.contributor.authorRaffi, François
dc.contributor.authorAllende, Luis M.
dc.contributor.authorMartinez-Picado, Javier
dc.contributor.authorOzcelik, Tayfun
dc.contributor.authorImberti, Luisa
dc.contributor.authorNotarangelo, Luigi D.
dc.contributor.authorTroya, Jesus
dc.contributor.authorSolanich, Xavier
dc.contributor.authorZhang, Shen-Ying
dc.contributor.authorPuel, Anne
dc.contributor.authorWilson, Michael R.
dc.contributor.authorTrouillet-Assant, Sophie
dc.contributor.authorAbel, Laurent
dc.contributor.authorJouanguy, Emmanuelle
dc.contributor.authorYe, Chun Jimmie
dc.contributor.authorCobat, Aurélie
dc.contributor.authorThompson, Leslie M.
dc.contributor.authorAndreakos, Evangelos
dc.contributor.authorZhang, Qian
dc.contributor.authorAnderson, Mark S.
dc.contributor.authorCasanova, Jean-Laurent
dc.contributor.authorDeRisi, Joseph L.
dc.date.accessioned2024-07-23T09:09:36Z
dc.date.available2024-07-23T09:09:36Z
dc.date.issued2023
dc.description.abstractLife-threatening "breakthrough" cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; their contribution to hypoxemic breakthrough cases in vaccinated people is unknown. We studied a cohort of 48 individuals (aged 20 to 86 years) who received two doses of a messenger RNA (mRNA) vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Ab levels to the vaccine, neutralization of the virus, and auto-Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal Ab response to the vaccine. Among them, 10 (24%) had auto-Abs neutralizing type I IFNs (aged 43 to 86 years). Eight of these 10 patients had auto-Abs neutralizing both IFN-α2 and IFN-ω, whereas two neutralized IFN-ω only. No patient neutralized IFN-β. Seven neutralized type I IFNs at 10 ng/ml and three at 100 pg/ml only. Seven patients neutralized SARS-CoV-2 D614G and Delta efficiently, whereas one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only type I IFNs at 100 pg/ml neutralized both D614G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating Abs capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a notable proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationBastard P, Vazquez SE, Liu J, et al. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci Immunol. 2023;8(90):eabp8966. doi:10.1126/sciimmunol.abp8966pt_PT
dc.identifier.doi10.1126/sciimmunol.abp8966pt_PT
dc.identifier.issn2470-9468
dc.identifier.urihttp://hdl.handle.net/10400.16/3012
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherAmerican Association for the Advancement of Sciencept_PT
dc.relation.publisherversionhttps://doi.org/10.1126/sciimmunol.abp8966pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.titleVaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceUnited States of Americapt_PT
oaire.citation.issue90pt_PT
oaire.citation.startPageeabp8966pt_PT
oaire.citation.titleScience Immunologypt_PT
oaire.citation.volume8pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Bastard-2023-Vaccine-breakthrough-hypoxemic-covi.pdf
Size:
795.95 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description: